A Phase 1, Open-Label, Randomized, Single Dose Study to Evaluate the Effect of Injection Site on the Pharmacokinetics of Astegolimab in Healthy Subjects
Latest Information Update: 04 Feb 2025
At a glance
- Drugs Astegolimab (Primary)
- Indications Allergic asthma; Atopic dermatitis; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Genentech
- 30 Jan 2025 Status changed from active, no longer recruiting to completed.
- 09 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 19 Jun 2024 New trial record